Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
intravenous delivery
Pharma
Merck moves a step closer with subcutaneous version of Keytruda
Marck revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating non-inferiority to intravenous Keytruda.
Kevin Dunleavy
Nov 19, 2024 10:20am
Otsuka forms joint venture to boost IV solution supply
Nov 14, 2024 8:40am
VacV exits stealth with systemic oncolytic viral delivery tech
Oct 31, 2022 9:15am
Mitsubishi Tanabe models economic impact of IV-to-oral switch
Aug 2, 2022 7:40am
Ready to prescribe Aduhelm? Docs detail why they will—or won't
Jun 8, 2021 7:40am
Siga seeks FDA approval for intravenous smallpox therapy
May 11, 2021 7:30am
